# Mercia Asset Management

> Mercia Asset Management is a VC fund backing Software. See 101 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Henley In Arden, United Kingdom
- Total investments: 101
- Last investment: Dec 2024
- Lead investor: 61%
- Last fund: Apr 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/mercia-asset-management/
- X (Twitter): https://twitter.com/Mercia_PLC
- Website: http://www.mercia.co.uk
- Facebook: https://www.facebook.com/MerciaPLC

Mercia Asset Management is a VC fund in Henley In Arden focused on Software and Information Technology. Mercia Asset Management invest across four distinct asset classes of venture, private equity and debt, referred to as our ‘Complete Capital Solution.Mercia Asset Management ision is to be the first choice for investors, investees and employees and, by aspiring to be the first choice, we believe that Mercia will deliver superior returns for businessowners, shareholders and fund investors alike.

## Contacts

5 contacts available for Mercia Asset Management. Shizune tracks 17 team members at Mercia Asset Management. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mercia-technologies?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $524k–$3.1M |
| Series A | $2.2M–$13M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 21 | 21% |
| Information Technology | 14 | 14% |
| Health Care | 10 | 10% |
| Manufacturing | 10 | 10% |
| Biotechnology | 8 | 8% |

107 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 25 | 25% |
| Series A | 18 | 18% |
| Seed | 16 | 16% |
| Venture - Series Unknown | 9 | 9% |
| Series B | 6 | 6% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 62 | 61% |
| United States | 2 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Aaron Lawson-Clark | Investment Director | 4 | https://shizune.co/investors/profile/aaron-lawson-clark-d240 |
| Julian Viggars | Chief Investment Officer | 9 | https://shizune.co/investors/profile/julian-viggars-829d |
| Martin Glanfield | Chief Financial Officer | 0 | https://shizune.co/investors/profile/martin-glanfield |
| Peter Dines | Chief Operating Officer & Head of Life Sciences & Biosciences | 19 | https://shizune.co/investors/profile/peter-dines |
| Ashwin Kumaraswamy | Investment Director | 4 | https://shizune.co/investors/profile/ashwin-kumaraswamy |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Netacea | Netacea offers a comprehensive bot management solution that safeguards enterprises from automated threats such as account takeover, credential stuffing, and web scraping. By utilizing behavior-based detection and machine learning, the platform operates seamlessly across websites, mobile apps, and APIs, enhancing operational efficiency and customerexperience. | $5.1M | Series A | Dec 06, 2024 |  |
| Semble | Semble is a healthcare technology company that develops practice management and electronic health record software for private healthcare providers. The company offers an integrated platform that combines patient records, appointment scheduling, telehealth, billing, payments, clinical documentation, prescribing, and care coordination tools within asingle system. Its software is designed to support the delivery and administration of healthcare services across clinics, medical practices, and multi-site healthcare organizations. The platform enables healthcare professionals to manage patient journeys from initial booking through consultation, treatment, follow-up care, and payment processing. It includes electronic health record functionality, clinical note management, patient communication tools, online booking capabilities, and workflow automation features that help streamline administrative and clinical processes.In addition to clinical and administrative functions, the company offers analytics, reporting, patient engagement, and automation tools that help healthcare organizations manage operations and monitor performance. Its solutions are used by a range of healthcare providers, including physicians, specialists, mental health professionals, physiotherapists, pharmacies, and occupational health organizations. | $15M | Series B | Oct 23, 2024 |  |
| Locate Bio | Locate Bio is a regenerative medicine development company focused on orthobiologics. Locate Bio exists to help surgeons improve the lives of people with debilitating spinal conditions. We are curious about what is possible, but ground all our work in robust scientific evidence. We relentlessly pursue high-value opportunities with clear unmetclinical needs. | $11.6M | Venture - Series Unknown | Apr 29, 2024 |  |
| Thalia Design Automation | Thalia Design Automation Ltd. operates as a semiconductor electronic design automation (EDA) company that provides software solutions to assist in the design of analog and mixed signal integrated circuits. | $2.7M |  | Jul 19, 2023 |  |
| The One Point | The One Point specializes in business mobiles, VoIP, broadband, IT support, printing, CRM, e-commerce and mobile app development services. | $1.8M | Debt Financing | Jul 11, 2023 |  |
| Camena Bioscience | Camena Bioscience is a synthetic biology company that develops tools to engineer new synthetic biology applications. It has engineered new nucleic acid synthesis technology which improves the quality and speed of synthesis. Its multi-enzymatic technology takes one approach to DNA, RNA, and XNA synthesis, offering increased accuracy over existingPhosphoramidite synthesis technology.Camena Bioscience was founded in 2016 and is headquartered in Cambridge. | $10.3M | Series A | Jul 03, 2023 |  |
| Medherant | Medherant was founded by Professor David Haddleton and the University of Warwick to develop and commercialise novel transdermal drug delivery platforms. Current patch technologies have limited drug loading capabilities, making them unviable for use with many pharmaceutical products that could benefit from transdermal delivery. Creams and gels onthe other hand suffer from a lack of dose control that is critical for many drugs. | $3.6M | Venture - Series Unknown | Apr 03, 2023 |  |
| Newcells Biotech | Newcells Biotech are experts in the production of induced pluripotent stem cells (iPSCs) and their differentiation into a wide range of reliable and reproducible cell and tissue types. Their focus is to provide customers engaged in drug discovery, pre-clinical development and disease mechanism investigation, with the best quality cells andservices. | $6.1M | Series A | Mar 16, 2023 |  |
| HowNow | HowNow is a London-based EdTech startup that connects experts and learners by offering interactive video lessons. It is an online platform that gives everyone the opportunity to learn from experts all over the world. HowNow's live online video classes mean that teachers and students can interact with one another as if they were in the sameroom. The company has more than 400 experts teaching in 33 countries. | $4.8M | Series A | Feb 06, 2023 |  |
| Send | Send Technology Solutions Ltd is a rapidly growing insurtech software company working with global industry leaders. | $10.7M | Series A | Nov 15, 2022 |  |

10 of 101 investments shown.

## Co-investors
- [Mercia Asset Management](https://shizune.co/investors/profile/mercia-asset-management) — VC Fund, 69 deals together
- [24 Haymarket](https://shizune.co/investors/profile/24-haymarket) — VC Fund, 4 deals together
- [Northern Powerhouse Investment Fund](https://shizune.co/investors/profile/northern-powerhouse-investment-fund) — VC Fund, 4 deals together
- [Par Equity](https://shizune.co/investors/profile/par-equity) — VC Fund, 4 deals together
- [Midven](https://shizune.co/investors/profile/midven) — VC Fund, 3 deals together
- [Techstars](https://shizune.co/investors/profile/techstars) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [All Investors in United Kingdom](https://shizune.co/investors/investors-united-kingdom)
- [All VC Funds in United Kingdom](https://shizune.co/investors/vc-funds-united-kingdom)
- [SaaS VC Funds in United Kingdom](https://shizune.co/investors/saas-vc-funds-united-kingdom)
- [SaaS Investors in United Kingdom](https://shizune.co/investors/saas-investors-united-kingdom)
- [Software Investors in United Kingdom](https://shizune.co/investors/software-investors-united-kingdom)
- [Software VC Funds in United Kingdom](https://shizune.co/investors/software-vc-funds-united-kingdom)

## FAQ

### What does Mercia Asset Management invest in?

Mercia Asset Management invests primarily in Software, Information Technology and Health Care startups, most often at Funding Round and Series A stage. Most of the 101 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Mercia Asset Management's check size?

Mercia Asset Management typically joins rounds of $524k–$3.1M at Seed and $2.2M–$13M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Mercia Asset Management participates in.

### How do I contact Mercia Asset Management?

Public channels for Mercia Asset Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mercia Asset Management?

The team at Mercia Asset Management includes Aaron Lawson-Clark (Investment Director), Julian Viggars (Chief Investment Officer) and Martin Glanfield (Chief Financial Officer), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co